Ftse Mib
37.843,68
-1,00%
DAX
22.465,10
-0,63%
S&P 500
5.602,24
-0,22%
NASDAQ
17.484,08
0,09%
Bitcoin
81.194,14
3,48%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cyclacel Pharmaceuticals Inc (CYCC) Cyclacel Pharmaceuticals Inc (CYCC) Notizie

CYCC

Cyclacel Pharmaceuticals (CYCC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYCC
DataOraFonteTitoloSimboloCompagnia
27/02/202519:38GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive LeadershipNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/01/202515:01GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David LazarNASDAQ:CYCCCyclacel Pharmaceuticals Inc
05/12/202422:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating CostsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/11/202422:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross ProceedsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
13/11/202418:22GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross ProceedsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
12/11/202422:45GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
24/10/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard RuleNASDAQ:CYCCCyclacel Pharmaceuticals Inc
23/10/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumNASDAQ:CYCCCyclacel Pharmaceuticals Inc
09/10/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumNASDAQ:CYCCCyclacel Pharmaceuticals Inc
25/09/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 StudyNASDAQ:CYCCCyclacel Pharmaceuticals Inc
04/09/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/09/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting LetterNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/08/202422:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/08/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
26/06/202415:15GlobeNewswire Inc.Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
04/06/202414:00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/06/202414:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/05/202422:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/05/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
02/05/202422:30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202419:51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202413:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
01/04/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202421:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202412:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CYCCCyclacel Pharmaceuticals Inc
13/03/202421:05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/03/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCCyclacel Pharmaceuticals Inc
06/03/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCCyclacel Pharmaceuticals Inc
20/02/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/01/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYCC

La tua Cronologia

BIT
ABT
Abitare In
NASDAQ
MNST
Monster Beverage
NASDAQ
GLAD
Gladstone Capital
NASDAQ
CEKLX
Ci Global Value Corporat...
BIT
S29092
Societe Generale Effekten
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci